Jensen Huang, Michael Dell, and Amancio Ortega exited the ranks of the very richest after stocks tumbled in the first quarter, denting their net worth.
The S&P 500 edged 0.4% higher on Tuesday, April 1, ahead of Wednesday's anticipated rollout of reciprocal tariffs by Donald Trump's administration.
WASHINGTON (Reuters) -A U.S. Senate investigative subcommittee on Tuesday opened a review into efforts by Facebook parent Meta Platforms to gain access to the Chinese market and is seeking documents from the company. Senator Ron Johnson, who chairs the Permanent Subcommittee on Investigations, joined by Senator Richard Blumenthal, the top Democrat, and Senator Josh Hawley, asked Meta CEO Mark Zuckerberg about allegations that it worked to build censorship tools for the Chinese Communist Party as part of its attempt to gain entry to the Chinese market, according to a letter seen by Reuters.
Tesla shares gained a day ahead of the electric vehicle maker's first-quarter deliveries data expected Wednesday.
Outdoor specialty retailer Sportsman's Warehouse (NASDAQ:SPWH) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, but sales fell by 8.1% year on year to $340.4 million. Its non-GAAP profit of $0.04 per share was significantly above analysts’ consensus estimates.
Bank software company nCino (NASDAQ:NCNO) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 14.3% year on year to $141.4 million. On the other hand, next quarter’s revenue guidance of $139.8 million was less impressive, coming in 4% below analysts’ estimates. Its non-GAAP profit of $0.12 per share was 35.1% below analysts’ consensus estimates.
Investors are looking ahead to President Trump's deadline to impose reciprocal tariffs on US trading partners creeps closer.
Charlie Javice, who faces a prison sentence of 14 to 17.5 years, unsuccessfully sought to portray JPMorgan Chase as careless.
Investors have come to a grim realization: President Donalf Trump's not in their corner.
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 12.5% in the afternoon session after the company revealed it will offer Eli Lilly's weight-loss medications (Zepbound) on its platform, marking a significant expansion beyond its previous focus on lower-cost alternatives to Novo Nordisk's Wegovy. This move positioned the company to tap into the growing demand for weight loss solutions and attract a broader customer base. The company added, "As we look ahead, we plan to continue t